Trump buys up ENTIRE stock of coronavirus drug remdesivir – sparking fury among medics – The Sun

THE US has bought up virtually all stocks of a drug shown to work against Covid-19 – raising fears Brits won't be able to get hold of it until autumn.

The decision by the Trump administration has sparked fury with leading scientists who have raised concerns over "fair access" to remdesivir.

⚠️ Read our coronavirus live blog for the latest news & updates

The anti-viral drug was originally developed for use against Ebola but trials showed that it helped patients hospitalised with coronavirus recover almost a third faster.

Health Secretary Matt Hancock hailed it the "biggest step forward" in treating Covid-19 when it was given approval for use on the NHS in May.

But now there are concerns patients in the UK won't get widespread access to the treatment after the US bought more than 500,000 doses.

It makes up the entire global supply for July and 90 per cent of stocks for August and September.

'Political pressure'

Oxford University's Professor Peter Horby, who led trials when the drug was first developed, said manufacturer Gilead would be under "certain political pressures locally" as a US company.

He told BBC Radio 4's Today programme: "It does raise two very important questions: what is a fair price for a drug and what is fair access to a drug, and those are common issues but are particularly important in a global crisis like this.

What is remdesivir?

Remdesivir is an experimental antiviral drug produced by the US pharmaceutical company Gilead, initially as a potential treatment for Ebola.

It was quickly pushed through clinical trials during the West African outbreak of 2013-15, after showing promising results in the lab, and was then rolled out more widely in affected areas of Africa.

Despite this, in 2019 Congolese health chiefs said the drug was less effective than first thought – and had a less significant impact on lowering death rates than monoclonal antibody drugs, which are often used for cancer treatment.

Remdesivir has been revived during the coronavirus pandemic.

This is because it showed promising results in preventing Middle East Respiratory Syndrome (Mers) and severe acute respiratory syndrome (Sars), which are also caused by coronaviruses.

How does it work?

The drug is given through an IV and is designed to interfere with the virus’s ability to copy its genetic material.

It is administered via daily infusion for about ten days.

What are the side effects?

In the Ebola trial, researchers noted that one side effect of remdesivir was increased liver enzyme levels that may indicate possible liver damage.

And researchers have since documented similar increases in liver enzymes in Covid-19 patients.

During one of Gilead Sciences trials, 23 per cent of those involved demonstrated evidence of liver damage on lab tests.

On top of this, about 25 per cent of patients receiving it had other severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure.

Typical antiviral drug side effects include nausea and vomiting.

"That's part of the fair access question, the trial that gave the result that allowed remdesivir to sell their drug wasn't just done in the US, there were patients participating through other European countries, in the UK as well, and internationally, Mexico and other places.

"And I wonder how they would feel knowing now that the drug is going to have restricted availability in their own country and would they have volunteered for that trial if they had known that?"

Vaccine concerns

Prof Horby, who now chairs the new and emerging respiratory virus threats advisory group (Nervtag), said also raises questions if a vaccine is found.

He told the radio show: "Commercial companies are built to behave like this and we need a much stronger framework if we are going to develop these things and they're going to be used for national emergencies."

Last night, the US Department of Health and Human Services (HSS) said it had secured more than 500,000 treatment courses of remdesivir for American hospitals.

This represents 100 per cent of the US pharmaceutical firm Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), alongside an allocation for clinical trials.

Remdesivir been approved for use in Covid-19 patients by the US and the UK, among other countries, after data suggested it can cut recovery time by about four days.

However, there is no clinical trial data as yet to suggest it improves survival from coronavirus.

It is one of two drugs which have been given the green light in treating coronavirus patients in the UK.

The other is dexamethasone – a £5 anti-inflammatory steroid proven to reduce the death rate among those requiring hospital ventilation for the bug.

US deal

HHS secretary Alex Azar said in a statement: "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19.

"To the extent possible, we want to ensure that any American patient who needs remdesivir can get it.

"The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people."

Gilead has said it will charge 2,340 US dollars (£1,900) for a typical treatment course for people in the US and other developed countries.

It will sell for less in poorer countries where generic drug-makers are being allowed to produce it.

Critics in the US attacked the price because taxpayers have funded much of the drug's development.

As of Tuesday, the US reported more than 2.7million cases of coronavirus of the world’s 10.5million.


Don't miss the latest news and figures – and essential advice for you and your family.

To receive The Sun's Coronavirus newsletter in your inbox every tea time, sign up here.
To follow us on Facebook, simply 'Like' our Coronavirus page.
Get Britain's best-selling newspaper delivered to your smartphone or tablet each day – find out more.


Nearly 130,000 Americans have died from the virus.

Remdesivir has been shown to shorten recovery time for severely ill coronavirus patients.

It’s given through an IV and interferes with the coronavirus strain’s ability to copy its genetic material.

Source: Read Full Article